We’ll help you find the highest quality medicine that you need.

Sabril

is indicated for the treatment of:

1) Refractory complex partial seizures as adjunctive therapy in patients ≥10 years of age who have responded inadequately to several alternative treatments

2) Infantile spasms–monotherapy in infants 1 month to 2 years of age for whom the potential benefits outweigh the potential risk of vision loss.

Manufactured by: Lundbeck Pharms, LLC

Active Ingredient(s): Vigabatrin

Dosage Form: Solution, oral

Strength: 500 mg/packet

FDA approved: August 21, 2009

More information about Sabril:

https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020427s016,022006s018lbl.pdf

https://www.lundbeck.com/upload/us/files/pdf/Products/Sabril_PI_US_EN.pdf

Syprine

is indicated for the treatment of patients with Wilson’s disease who are intolerant of Penicillamine.

Manufactured by: Valeant Pharmaceuticals North America, LLC

Active Ingredient(s): Trientine Hydrochloride 

Dosage Form: Capsule, oral

Strength: 250 mg

FDA approved: November 8, 1985

More information about Syprine:

http://www.valeant.com/Portals/25/Pdf/PI/Syprine-PI.pdf

Sutent

is indicatedfor the treatment of renal cell carcinoma (RCC) and Imatinib-resistant gastrointestinal stromal tumor.

Manufactured by: Pfizer, Inc.

Active Ingredient(s): Sunitinib Malate 

Dosage Form: Capsules, oral

Strength: 12.5 mg, 50 mg

FDA approved: May 20, 2011(First approval26th January, 2006)

More information about Sutent:

https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021968lbl.pdf

http://labeling.pfizer.com/showlabeling.aspx?id=607

Sovaldi

is indicated for the treatment of chronic hepatitis C (CHC) infection as a component of a combination antiviral treatment regimen. Sovaldi efficacy has been established in subjects with HCV genotype 1, 2, 3 or 4 infection, including those with hepatocellular carcinoma meeting Milan criteria (awaiting liver transplantation) and those with HCV/HIV-1 co-infection.

Manufactured by: Gilead Sciences, Inc

Active Ingredient(s): Sofosbuvir

Dosage Form: Tablet, oral

Strength: 400 mg

FDA approved: December 6, 2013

More information about Sovaldi:

https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204671s000lbl.pdf

http://www.gilead.com/~/media/Files/pdfs/medicines/liver-disease/sovaldi/sovaldi_pi.pdf

Interested in a product you don’t see? Please contact us with an inquiry. We may be able to find it for you.